Ken Griffin’s Oragenics OGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-550
Closed -$17.2K 14934
2024
Q2
$17.2K Buy
+550
New +$24.9K ﹤0.01% 12760
2023
Q1
Sell
-48
Closed -$9.11K 15266
2022
Q4
$9.11K Buy
+48
New +$16.9K ﹤0.01% 13707
2022
Q1
Sell
-30
Closed -$24K 14291
2021
Q4
$24K Sell
30
-45
-60% -$45.5K ﹤0.01% 13546
2021
Q3
$86K Buy
+75
New +$90.5K ﹤0.01% 13009
2021
Q2
Sell
-206
Closed -$336K 14192
2021
Q1
$336K Buy
206
+90
+78% +$163K ﹤0.01% 10572
2020
Q4
$94K Buy
116
+96
+480% +$84.5K ﹤0.01% 10261
2020
Q3
$21K Buy
+20
New +$32K ﹤0.01% 9844
2018
Q4
Sell
-17
Closed -$35K 9583
2018
Q3
$35K Buy
+17
New +$19.6K ﹤0.01% 8890
2018
Q1
Sell
-2
Closed -$10K 8626
2017
Q4
$10K Buy
+2
New +$12.6K ﹤0.01% 7893
2017
Q3
Sell
-3
Closed -$18K 7877
2017
Q2
$18K Buy
3
+1
+50% +$7.41K ﹤0.01% 7306
2017
Q1
$13K Buy
+2
New +$21.5K ﹤0.01% 7325
2016
Q3
Sell
-2
Closed -$17K 7596
2016
Q2
$17K Buy
2
+1
+100% +$13.4K ﹤0.01% 6667
2016
Q1
$13K Buy
+1
New +$18.3K ﹤0.01% 6570
2015
Q2
Sell
-1
Closed -$17K 8962
2015
Q1
$17K Hold
1
﹤0.01% 8014
2014
Q4
$16K Hold
1
﹤0.01% 7957
2014
Q3
$18K Buy
+1
New +$29.8K ﹤0.01% 7525
2014
Q2
Sell
-1
Closed -$54K 8195
2014
Q1
$54K Buy
+1
New +$60.7K ﹤0.01% 6721

Other funds holding OGEN

Ken Griffin's OGEN Position: Q3 2024 in Review

Ken Griffin sold out of Oragenics (OGEN) in Q3 2024, closing a stake of 550 shares — an estimated $17.2K sold.

Ken Griffin first reported a position in OGEN in Q1 2014 and held it in 17 quarters. The position peaked at $336K in Q1 2021. 13 funds tracked by Wall St. Rank hold OGEN as of Q3 2024.

  • Ken Griffin reported no remaining Oragenics position as of Q3 2024 after selling out during the quarter.
  • Ken Griffin sold 550 Oragenics shares in Q3 2024, an estimated $17.2K.
  • Ken Griffin first reported a position in Oragenics in Q1 2014 and held it in 17 quarters.
  • Ken Griffin's Oragenics position peaked at $336K in Q1 2021.
  • 13 funds tracked by Wall St. Rank held Oragenics as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.